Treatments directly targeting CD19 antigen (Blinatumomab or chimeric antigen receptor T‐cell therapy (CAR‐T)) were used in 12 cases (10 B‐ALL and two follicular lymphoma cases; Table S1). Here, CD19 is linked to follicular lymphoma.